Potential drug–drug interactions in HIV-infected children on antiretroviral therapy in Lagos, Nigeria

Potential drug–drug interactions in HIV-infected children on antiretroviral therapy in Lagos, Nigeria

Kazeem A Oshikoya,1 Ibrahim A Oreagba,2 Saheed Lawal,2 Olufunsho Awodele,2 Olayinka O Ogunleye,1 Idowu O Senbanjo,3 Sunday O Olayemi,2 Veronica C Ezeaka,4,5 Edamisan O Temiye,4,5 Titilope A Adeyemo,4,6 Oluranti Opanuga,4,7 Olufunmilayo A Lesi,4,8 Sulaimon A Akanmu4,6 1Department of Pharmacology, La...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Oshikoya KA, Oreagba IA, Lawal S, Awodele O, Ogunleye OO, Senbanjo IO, Olayemi SO, Ezeaka VC, Temiye EO, Adeyemo TA, Opanuga O, Lesi OA, Akanmu SA
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2014
Materias:
Immunologic diseases. Allergy
RC581-607
Acceso en línea:https://doaj.org/article/d53fa1cedd62467d8f330a3e388ff24a
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:d53fa1cedd62467d8f330a3e388ff24a
record_format dspace
spelling oai:doaj.org-article:d53fa1cedd62467d8f330a3e388ff24a2021-12-02T04:43:18ZPotential drug–drug interactions in HIV-infected children on antiretroviral therapy in Lagos, Nigeria1179-1373https://doaj.org/article/d53fa1cedd62467d8f330a3e388ff24a2014-04-01T00:00:00Zhttp://www.dovepress.com/potential-drugndashdrug-interactions-in-hiv-infected-children-on-antir-a16353https://doaj.org/toc/1179-1373 Kazeem A Oshikoya,1 Ibrahim A Oreagba,2 Saheed Lawal,2 Olufunsho Awodele,2 Olayinka O Ogunleye,1 Idowu O Senbanjo,3 Sunday O Olayemi,2 Veronica C Ezeaka,4,5 Edamisan O Temiye,4,5 Titilope A Adeyemo,4,6 Oluranti Opanuga,4,7 Olufunmilayo A Lesi,4,8 Sulaimon A Akanmu4,6 1Department of Pharmacology, Lagos State University College of Medicine, Ikeja, Lagos, Nigeria; 2Department of Pharmacology, College of Medicine, University of Lagos, Idi-Araba, Lagos, Nigeria; 3Department of Paediatrics, Lagos State University College of Medicine, Ikeja, Lagos, Nigeria; 4APIN Clinic, Lagos University Teaching Hospital, Lagos, Nigeria; 5Department of Paediatrics, College of Medicine, University of Lagos, Idi-Araba, Lagos, Nigeria; 6Department of Haematology and Blood Transfusion, College of Medicine, University of Lagos, Idi-Araba, Lagos, Nigeria; 7Department of Pharmacy, Lagos University Teaching Hospital, Idi-Araba Lagos, Nigeria; 8Department of Medicine, College of Medicine, University of Lagos, Idi-Araba, Lagos, Nigeria Background: Multi-therapy is common in HIV-infected children, and the risk for clinically significant drug interactions (CSDIs) is high. We investigated the prevalence of CSDIs between antiretroviral (ARV) and co-prescribed drugs for children attending a large HIV clinic in Lagos, Nigeria. Methods: The case files of pediatric patients receiving treatment at the HIV clinic of the Lagos University Teaching Hospital (LUTH), Idi-Araba, between January 2005 and December 2010 were reviewed. The ARV and co-prescribed drug pairs were evaluated for potential interactions using the Liverpool HIV Pharmacology Group website. The potential interactions were rated as A (no known interaction), B (minor/no action needed), C (moderate/monitor therapy), D (major/therapy modification), and X (contraindicated/avoid combination). Results: Of the 310 cases reviewed, 208 (67.1%) patients were at risk of CSDIs. Artemisinin-based combination therapy was prescribed for over one-half of the patients, accounting for 40% of the CSDIs. Excluding this drug class, the prevalence of CSDIs reduced from 67.1% to 18.7% in 58 patients. Most of the CSDIs (579; 97.2%) were moderately significant and frequently involved nevirapine and fluconazole (58; 9.7%), zidovudine and fluconazole (55; 9.2%), zidovudine and rifampicin (35; 5.9%), and nevirapine and prednisolone (31; 5.2%). Age (P=0.392), sex (P=0.783), and moderate (P=0.632) or severe (P=0.755) malnutrition were not associated with risk for CSDIs. Conclusion: There is a tendency for CSDIs between ARV and co-prescribed drugs among the group of children evaluated in this study. Measures are necessary to prevent important drug interactions and to manage those that are unavoidable. Keywords: infection, antiretroviral drug, co-prescribed drug, prevalence, therapy monitoring, therapy modification, contraindicationOshikoya KAOreagba IALawal SAwodele OOgunleye OOSenbanjo IOOlayemi SOEzeaka VCTemiye EOAdeyemo TAOpanuga OLesi OAAkanmu SADove Medical PressarticleImmunologic diseases. AllergyRC581-607ENHIV/AIDS: Research and Palliative Care, Vol 2014, Iss default, Pp 49-59 (2014)
institution DOAJ
collection DOAJ
language EN
topic Immunologic diseases. Allergy
RC581-607
spellingShingle Immunologic diseases. Allergy
RC581-607
Oshikoya KA
Oreagba IA
Lawal S
Awodele O
Ogunleye OO
Senbanjo IO
Olayemi SO
Ezeaka VC
Temiye EO
Adeyemo TA
Opanuga O
Lesi OA
Akanmu SA
Potential drug–drug interactions in HIV-infected children on antiretroviral therapy in Lagos, Nigeria
description Kazeem A Oshikoya,1 Ibrahim A Oreagba,2 Saheed Lawal,2 Olufunsho Awodele,2 Olayinka O Ogunleye,1 Idowu O Senbanjo,3 Sunday O Olayemi,2 Veronica C Ezeaka,4,5 Edamisan O Temiye,4,5 Titilope A Adeyemo,4,6 Oluranti Opanuga,4,7 Olufunmilayo A Lesi,4,8 Sulaimon A Akanmu4,6 1Department of Pharmacology, Lagos State University College of Medicine, Ikeja, Lagos, Nigeria; 2Department of Pharmacology, College of Medicine, University of Lagos, Idi-Araba, Lagos, Nigeria; 3Department of Paediatrics, Lagos State University College of Medicine, Ikeja, Lagos, Nigeria; 4APIN Clinic, Lagos University Teaching Hospital, Lagos, Nigeria; 5Department of Paediatrics, College of Medicine, University of Lagos, Idi-Araba, Lagos, Nigeria; 6Department of Haematology and Blood Transfusion, College of Medicine, University of Lagos, Idi-Araba, Lagos, Nigeria; 7Department of Pharmacy, Lagos University Teaching Hospital, Idi-Araba Lagos, Nigeria; 8Department of Medicine, College of Medicine, University of Lagos, Idi-Araba, Lagos, Nigeria Background: Multi-therapy is common in HIV-infected children, and the risk for clinically significant drug interactions (CSDIs) is high. We investigated the prevalence of CSDIs between antiretroviral (ARV) and co-prescribed drugs for children attending a large HIV clinic in Lagos, Nigeria. Methods: The case files of pediatric patients receiving treatment at the HIV clinic of the Lagos University Teaching Hospital (LUTH), Idi-Araba, between January 2005 and December 2010 were reviewed. The ARV and co-prescribed drug pairs were evaluated for potential interactions using the Liverpool HIV Pharmacology Group website. The potential interactions were rated as A (no known interaction), B (minor/no action needed), C (moderate/monitor therapy), D (major/therapy modification), and X (contraindicated/avoid combination). Results: Of the 310 cases reviewed, 208 (67.1%) patients were at risk of CSDIs. Artemisinin-based combination therapy was prescribed for over one-half of the patients, accounting for 40% of the CSDIs. Excluding this drug class, the prevalence of CSDIs reduced from 67.1% to 18.7% in 58 patients. Most of the CSDIs (579; 97.2%) were moderately significant and frequently involved nevirapine and fluconazole (58; 9.7%), zidovudine and fluconazole (55; 9.2%), zidovudine and rifampicin (35; 5.9%), and nevirapine and prednisolone (31; 5.2%). Age (P=0.392), sex (P=0.783), and moderate (P=0.632) or severe (P=0.755) malnutrition were not associated with risk for CSDIs. Conclusion: There is a tendency for CSDIs between ARV and co-prescribed drugs among the group of children evaluated in this study. Measures are necessary to prevent important drug interactions and to manage those that are unavoidable. Keywords: infection, antiretroviral drug, co-prescribed drug, prevalence, therapy monitoring, therapy modification, contraindication
format article
author Oshikoya KA
Oreagba IA
Lawal S
Awodele O
Ogunleye OO
Senbanjo IO
Olayemi SO
Ezeaka VC
Temiye EO
Adeyemo TA
Opanuga O
Lesi OA
Akanmu SA
author_facet Oshikoya KA
Oreagba IA
Lawal S
Awodele O
Ogunleye OO
Senbanjo IO
Olayemi SO
Ezeaka VC
Temiye EO
Adeyemo TA
Opanuga O
Lesi OA
Akanmu SA
author_sort Oshikoya KA
title Potential drug–drug interactions in HIV-infected children on antiretroviral therapy in Lagos, Nigeria
title_short Potential drug–drug interactions in HIV-infected children on antiretroviral therapy in Lagos, Nigeria
title_full Potential drug–drug interactions in HIV-infected children on antiretroviral therapy in Lagos, Nigeria
title_fullStr Potential drug–drug interactions in HIV-infected children on antiretroviral therapy in Lagos, Nigeria
title_full_unstemmed Potential drug–drug interactions in HIV-infected children on antiretroviral therapy in Lagos, Nigeria
title_sort potential drug–drug interactions in hiv-infected children on antiretroviral therapy in lagos, nigeria
publisher Dove Medical Press
publishDate 2014
url https://doaj.org/article/d53fa1cedd62467d8f330a3e388ff24a
work_keys_str_mv AT oshikoyaka potentialdrugndashdruginteractionsinhivinfectedchildrenonantiretroviraltherapyinlagosnigeria
AT oreagbaia potentialdrugndashdruginteractionsinhivinfectedchildrenonantiretroviraltherapyinlagosnigeria
AT lawals potentialdrugndashdruginteractionsinhivinfectedchildrenonantiretroviraltherapyinlagosnigeria
AT awodeleo potentialdrugndashdruginteractionsinhivinfectedchildrenonantiretroviraltherapyinlagosnigeria
AT ogunleyeoo potentialdrugndashdruginteractionsinhivinfectedchildrenonantiretroviraltherapyinlagosnigeria
AT senbanjoio potentialdrugndashdruginteractionsinhivinfectedchildrenonantiretroviraltherapyinlagosnigeria
AT olayemiso potentialdrugndashdruginteractionsinhivinfectedchildrenonantiretroviraltherapyinlagosnigeria
AT ezeakavc potentialdrugndashdruginteractionsinhivinfectedchildrenonantiretroviraltherapyinlagosnigeria
AT temiyeeo potentialdrugndashdruginteractionsinhivinfectedchildrenonantiretroviraltherapyinlagosnigeria
AT adeyemota potentialdrugndashdruginteractionsinhivinfectedchildrenonantiretroviraltherapyinlagosnigeria
AT opanugao potentialdrugndashdruginteractionsinhivinfectedchildrenonantiretroviraltherapyinlagosnigeria
AT lesioa potentialdrugndashdruginteractionsinhivinfectedchildrenonantiretroviraltherapyinlagosnigeria
AT akanmusa potentialdrugndashdruginteractionsinhivinfectedchildrenonantiretroviraltherapyinlagosnigeria
_version_ 1718401101475086336

Ejemplares similares